Image by Doug Wallick via FlickrInvestors are finally realizing the potential turnaround at Boston Scientific. Stock is frequently on the Most Active List and the volume is monstrous. Traditional technical analysis interprets the chart as ...
OUR BUY SIGNAL IN THE FACE OF MULTIPLE DOWNGRADES BY THE WALL STREET ON $BSX (BOSTON SCIENTIFIC) HAS PROVEN TO BE THE CORRECT CALL
On March 15,2010 when Boston Scientific's defibrillators were taken off the market, the Wall Street uniformly issued downgrades. Goldman Sachs downgraded to Conviction Sell.: JP Morgan said sell, Barron's urged investors to sell and the ...
FDA APPROVES EXPANDED USE OF $BSX (BOSTON SCIENTIFIC) DEVICES
Typically we refrain from posting on this blog the information that is easily available elsewhere. In view of us taking long position on BSX immediately after seven broker downgrades and the importance of this FDA ...
NOBLE ON $BSX
Noble Financial's checks at Boston Scientific indicate ICD's and CRT-Ds could return back to the market in 5 days versus some market expectations of months.www.thearorareport.com
THE ARORA REPORT, Ltd.
HOME OF THE UNIQUE ZYX CHANGE METHOD
DEDICATED SOLELY ...
12.5% GAIN ON $BSX (BOSTON SCIENTIFIC) IN THE FACE OF SEVERAL BROKER DOWNGRADES
In spite of a negative article in Barron's Online and two new broker downgrades, we have 12.5% gain at $7.10. This illustrates the power of ZYX Change Method. ZYX Change Method calls for ...
ANATOMY OF $BSX (BOSTON SCIENTIFIC), $MDT (MEDTRONIC) AND $STJ (ST. JUDE MEDICAL) TRADES BASED ON ZYX CHANGE METHOD
In ZYX Change Method, every trade must pass through six screens. In the first Change Screen, we are looking for macro changes. In this case, our long time readers know that we have ...
AS PER THE PRIOR POST, SCALED IN LONG ON $BSX AT $6.32
www.thearorareport.com
THE ARORA REPORT, Ltd.
HOME OF THE UNIQUE ZYX CHANGE METHOD
DEDICATED SOLELY TO PROFIT FROM CHANGE BY TRADING AND INVESTING
VERIFIABLE PERFORMANCE RECORD
Every closed trade since 2007, without exception, is included in the performance results.
Number of ...
SHORT SELL $STJ AND $MDT, BUY $BSX
$BSX is down substantially on FDA issues and competitors $MDT and $STJ have spiked up. These are minor paperwork issues and will not have a long term impact. Scale in on $BSX on dips. Scale ...
$BSX (BOSTON SCIENTIFIC) EARNINGS CONFIRM OUR SHORT SELL THESIS
We have been short on $MDT (Medtronics) with the first scale in at $36.20 and more aggressive entry at $38.00. $BSX earnings show weakness in both stents and implantable cardiac devices. Going forward ...
CHECK OUR PERFORMANCE
